Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 14:17:3899-3913.
doi: 10.2147/OPTH.S439457. eCollection 2023.

Alternatives to Topical Glaucoma Medication for Glaucoma Management

Sahar Bedrood  1 , John Berdahl  2 , Arsham Sheybani  3   4 , Inder Paul Singh  5
Affiliations

Alternatives to Topical Glaucoma Medication for Glaucoma Management

Sahar Bedrood et al. Clin Ophthalmol. .

Abstract

Topical glaucoma medications have favorable safety and efficacy, but their use is limited by factors such as side effects, nonadherence, costs, ocular surface disease, intraocular pressure fluctuations, diminished quality of life, and the inherent difficulty of penetrating the corneal surface. Although traditionally these limitations have been accepted as an inevitable part of glaucoma treatment, a rapidly-evolving arena of minimally invasive surgical and laser interventions has initiated the beginnings of a reevaluation of the glaucoma treatment paradigm. This reevaluation encompasses an overall shift away from the reactive, topical-medication-first default and a shift toward earlier intervention with laser or surgical therapies such as selective laser trabeculoplasty, sustained-release drug delivery, and micro-invasive glaucoma surgery. Aside from favorable safety, these interventions may have clinically important attributes such as consistent IOP control, cost-effectiveness, independence from patient adherence, prevention of disease progression, and improved quality of life.

Keywords: MIGS; intervention; medication; selective laser trabeculoplasty; sustained release drug delivery; treatment.

PubMed Disclaimer

Conflict of interest statement

SB: Allergan: speaker, consultant; Glaukos: Speaker, consultant; Thea Laboratories: consultant; Ocular Therapeutix: consultant; BVI: consultant; MST: consultant; Belkin: consultant; Elios Vision: consultant. JB: AbbVie (C, L); Aerie (C); Aerpio (C); Alcon (C, L); Aldeyra (C); Aurea Medical (C) Aurion Biotech/CorneaG (C, O); Balance Ophthalmics (C); Bausch + Lomb (C); Dakota Lions Eye Bank (C); Elios Vision INC (C); Equinox (C, O); Expert Opinion (C, O); Glaukos (C, L); Gore (C); Iacta Pharmaceuticals (C); Imprimis (C, P); Interfeen (C); iRenix (C); IVERIC Bio, Inc (C); Johnson & Johnson (C); Kala (C); Kedalion (C); MELT Pharmaceuticals (C); MicroOptx (C); New World Medical (C); Ocular Surgical Data (C, O); Ocular Theraputix (C); Omega Ophthalmic (C, O); Orasis (C); Oyster Point (C); RxSight (C); Santen (C); Sight Sciences (C); Surface Inc (C, O); Tarsus (C); Tear Clear (C); RxSight (C); Vance Thompson Vision (C, O); Verana Health (O); Versea Biologics (C); Vertex Ventures (C); ViaLase (C); Visionary Ventures (C); Visus (C); VittamedB40 (C); Zeiss (C, O). A.S. reports the following disclosures: Alcon, Nova Eye, AbbVie, and Glaukos. IPS is a speaker and consultant for Glaukos, Allergan, BVI, New World Medical, Ivantis, Sight Sciences, Ocular Therapeutix, Sun Pharmaceuticals, Novartis, Nova Eye, Bausch + Lomb, Kala Pharmaceuticals, and EyePoint Pharmaceuticals. The authors report no other conflicts of interest in this work.

References

    1. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713. doi:10.1001/archopht.120.6.701 - DOI - PubMed
    1. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108(11):1943–1953. - PubMed
    1. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268–1279. - PubMed
    1. Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385(9975):1295–1304. doi:10.1016/S0140-6736(14)62111-5 - DOI - PubMed
    1. Migdal C, Gregory W, Hitchings R. Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology. 1994;101(10):1651–1656. - PubMed